News Agency
Men's Weekly

LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA

  • Written by PR Newswire

First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseases

SEOUL, South Korea, Dec. 8, 2022 /PRNewswire/ -- LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been designated as an orphan drug by the US FDA.

On December 1,...

Read more: LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA

How Signage Shapes Business Visibility And Customer Perception

In today’s competitive commercial environment, signage is far more than just a display element—it acts as a silent communicator between a business and its audience. Whether positioned outdoors or within a retail or corporate space, it provides immediate information about what... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion